Lecanemab for posterior cortical atrophy: Two contrasting cases

Learning Objectives:

1. Explain why global cognitive screening tools may underestimate disease severity in patients with posterior cortical atrophy (PCA).

2. Describe the essential components of a multimodal framework for monitoring disease progression in patients with PCA receiving anti-amyloid antibody treatment.

Katsuse, K., Kakinuma, K., Niimi, Y., Iseki, C., Kawakami, N., Ota, S., … Suzuki, K. (2025). Lecanemab for posterior cortical atrophy: Two contrasting cases. The Clinical Neuropsychologist, 1–23. https://doi.org/10.1080/13854046.2025.2590527

$20.00 – Purchase Checkout Added to cart